

---

## AUSTRALIAN PRODUCT INFORMATION

### **SUDAFED® Sinus + Allergy & Pain Relief Tablets (Paracetamol, Pseudoephedrine hydrochloride, Triprolidine hydrochloride)**

---

#### **1 Name of the Medicine**

Paracetamol

Pseudoephedrine Hydrochloride

Triprolidine Hydrochloride

#### **2 Qualitative and Quantitative Composition**

SUDAFED® Sinus + Allergy & Pain Relief tablets contain pseudoephedrine hydrochloride 30 mg, paracetamol 500 mg and triprolidine hydrochloride 1.25 mg.

For the full list of excipients, see Section 6.1 List of excipients.

#### **3 Pharmaceutical Form**

SUDAFED® Sinus + Allergy & Pain Relief tablets are turquoise, bevelled, capsule-shaped, flat and uncoated. They are scored on one face and coded 'S3F' each side of the score, and plain on the other face.

#### **4 Clinical Particulars**

##### **4.1 Therapeutic Indications**

SUDAFED® Sinus + Allergy & Pain Relief provides temporary relief of severe sinus pain & congestion, nasal congestion, headache & pain, allergic symptoms such as sneezing, itching and watery eyes.

##### **4.2 Dose and Method of Administration**

The recommended dosage of SUDAFED® Sinus + Allergy & Pain Relief for adults and children over 12 years is two tablets 3 to 4 times daily. Do not exceed the recommended dosage.

SUDAFED® Sinus + Allergy & Pain Relief should not be used for children under 12 years of age without medical advice.

##### **Use in adults**

Paracetamol should not be taken for more than a few days at a time except on medical advice.

##### **Use in children**

Paracetamol should not be taken for more than 48 hours except on medical advice.

### 4.3 Contraindications

Pseudoephedrine is contraindicated for use in patients:

- with known hypersensitivity or idiosyncratic reaction to pseudoephedrine (or any of the other ingredients in the product)
- with severe hypertension or coronary artery disease
- taking monoamine oxidase inhibitors (MAOIs) or who have taken MAOIs within the previous 14 days.

Paracetamol is contraindicated for use in patients with known hypersensitivity or idiosyncratic reaction to paracetamol (or any of the other ingredients in the product).

Tripolidine is contraindicated for use in patients with:

- a history of hypersensitivity to tripolidine or substances of similar chemical structure (or any of the other ingredients in the product)
- narrow-angle glaucoma
- stenosing peptic ulcer
- symptomatic prostatic hypertrophy
- bladder neck obstruction
- with pyloroduodenal obstruction.

Tripolidine is contraindicated for use in:

- newborns or premature infants
- lactating women
- patients taking monoamine oxidase inhibitors (MAOIs).

Refer to '4.5 Interactions with other medicines and other forms of interactions' for additional information.

### 4.4 Special Warnings and Precautions for Use

Pseudoephedrine should be used with caution in patients with:

- hypertension
- hyperthyroidism or thyroid disease
- diabetes mellitus
- coronary heart disease
- ischaemic heart disease
- glaucoma
- prostatic hypertrophy
- severe hepatic or renal dysfunction.

Some cases of ischaemic colitis have been reported with pseudoephedrine.

Pseudoephedrine should be discontinued and medical advice sought if sudden abdominal pain, rectal bleeding or other symptoms of ischaemic colitis develop.

If signs and symptoms such as formation of small pustules occur, with or without pyrexia or erythema, then treatment with pseudoephedrine should be discontinued and a physician should be consulted.

Serious skin reactions such as acute generalized exanthematous pustulosis

(AGEP), Stevens - Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) and drug reaction with eosinophilia and systemic symptoms (DRESS) have been reported very rarely in patients receiving paracetamol. Patients should be informed about the signs of serious skin reactions and use of the drug should be discontinued at the first appearance of skin rash or any other sign of hypersensitivity.

Paracetamol should be used with caution in patients with:

- impaired hepatic function
- impaired renal function
- chronic alcoholism

Triprolidine may cause drowsiness and may increase the effects of alcohol. Drowsiness may continue the following day. Those affected should not drive or operate machinery; alcohol should be avoided.

Use with caution in patients with renal or hepatic impairment, patients with epilepsy, and patients with respiratory conditions such as emphysema, chronic bronchitis, or acute or chronic bronchial asthma.

Refer to 'Interactions with other medicines and other forms of interactions' for additional information.

#### **Use in hepatic impairment**

Use with caution in patients with hepatic impairment or severe hepatic dysfunction.

#### **Use in renal impairment**

Use with caution in patients with renal impairment or severe renal dysfunction.

#### **Use in elderly**

The elderly may experience paradoxical excitation with triprolidine. The elderly are more likely to have CNS depressive side effects, including confusion.

#### **Paediatric use**

Children may experience paradoxical excitation with triprolidine.

#### **Effects on laboratory tests**

No data available.

## **4.5 Interactions with other medicines and other forms of interactions**

The following interactions with pseudoephedrine have been noted:

- antidepressant medication eg tricyclic antidepressants and monoamine oxidase inhibitors (MAOIs) – may cause a serious increase in blood pressure or hypertensive crisis
- other sympathomimetic agents, such as decongestants, appetite suppressants and amphetamine-like psychostimulants – may cause an increase in blood pressure and additive effects
- methyldopa and  $\beta$ -blockers – may cause an increase in blood pressure
- urinary acidifiers enhance elimination of pseudoephedrine
- urinary alkalinisers decrease elimination of pseudoephedrine.

The following interactions with paracetamol have been noted:

- anticoagulant drugs (warfarin) - dosage may require reduction if paracetamol and anticoagulants are taken for a prolonged period of time
- paracetamol absorption is increased by substances that increase gastric emptying, e.g. metoclopramide
- paracetamol absorption is decreased by substances that decrease gastric emptying, e.g. propantheline, antidepressants with anticholinergic properties, and narcotic analgesics
- paracetamol may increase chloramphenicol concentrations
- the risk of paracetamol toxicity may be increased in patients receiving other potentially hepatotoxic drugs or drugs that induce liver microsomal enzymes such as alcohol and anticonvulsant agents
- paracetamol excretion may be affected and plasma concentrations altered when given with probenecid
- colestyramine reduces the absorption of paracetamol if given within 1 hour of paracetamol
- high anion gap metabolic acidosis from pyroglutamic acid (5-oxoprolinemia) has been reported with concomitant use of therapeutic doses of paracetamol and flucloxacillin. Patients reported to be most at risk are elderly females with underlying disease such as sepsis, renal function abnormality, and malnutrition.

The following interactions with triprolidine have been noted:

- CNS depressants (alcohol, sedatives, opioid analgesics, hypnotics) – may cause an increase in sedation effects
- monoamine oxidase inhibitors (MAOIs) and tricyclic antidepressants (TCAs) – may prolong and intensify the anticholinergic and CNS depressive effects.

## 4.6 Fertility, Pregnancy and Lactation

### Effects on Fertility

No Data available.

### Use in pregnancy

The pregnancy categorisation is B2. Pseudoephedrine has been taken by only a limited number of pregnant women and women of childbearing age, without an increase in the frequency of malformation or other direct or indirect harmful effects on the human foetus having been observed. Studies in animals are inadequate or may be lacking, but available data shows no evidence of an increased occurrence of foetal damage.

Pseudoephedrine should be used in pregnancy only if the potential benefits to the patient are weighed against the possible risk to the foetus.

Paracetamol has been taken by a large number of pregnant women and women of childbearing age without any proven increase in the frequency of malformations or other direct or indirect harmful effects on the foetus having been observed.

Triprolidine has been taken by a large number of pregnant women and women of childbearing age without any proven increase in the frequency of malformations or

other direct or indirect harmful effects on the foetus having been observed.

### Use in lactation

Pseudoephedrine is secreted in breast milk in small amounts. It has been estimated that 0.5% to 0.7% of a single dose of pseudoephedrine ingested by the mother will be excreted in the breast milk over 24 hours. Therefore, it is not recommended for breastfeeding mothers unless the potential benefits to the patient are weighed against the possible risk to the infant.

Paracetamol is excreted in small amounts (< 0.2%) in breast milk. Maternal ingestion of paracetamol in usual analgesic doses does not appear to present a risk to the breastfed infant.

Triprolidine is excreted in breast milk. Therefore it is not recommended for breastfeeding mothers unless the potential benefits to the patient are weighed against the possible risk to the infant.

## 4.7 Effects on the ability to drive and use machines

Triprolidine may cause drowsiness and may increase the effects of alcohol. Drowsiness may continue the following day. Those affected should not drive or operate machinery; alcohol should be avoided.

## 4.8 Adverse Effects (Undesirable Effects)

Children and the elderly are more likely to experience adverse effects than other age groups.

Adverse drug reactions identified during post-marketing experience with paracetamol, pseudoephedrine, the combination of pseudoephedrine and triprolidine, the combination of pseudoephedrine and paracetamol or the combination paracetamol, pseudoephedrine and triprolidine appear in the following table. The frequency category was estimated from spontaneous reporting rates according to the following convention:

Very common	≥1/10
Common	≥1/100 and < 1/10
Uncommon	≥1/1,000 and <1/100
Rare	≥1/10,000 and <1/1,000
Very rare	<1/10,000
Not known (cannot be estimated from the available data)	

<i>Frequency category</i>	<i>Adverse Event Preferred Term</i>
<b>Immune System Disorders</b>	
Very Rare	<i>Anaphylactic reaction</i>
Very Rare	<i>Hypersensitivity</i>
<b>Psychiatric Disorders</b>	
Very Rare	<i>Hallucination</i>

Very Rare	<i>Anxiety</i>
Very Rare	<i>Euphoric mood</i>
Very Rare	<i>Insomnia</i>
Very Rare	<i>Nervousness</i>
Very Rare	<i>Restlessness</i>
Very Rare	<i>Irritability</i>
Very Rare	<i>Hallucination visual</i>
<b>Nervous System Disorders</b>	
Very Rare	<i>Cerebrovascular accident*</i>
Very Rare	<i>Dizziness</i>
Very Rare	<i>Headache</i>
Very Rare	<i>Paraesthesia</i>
Very Rare	<i>Psychomotor hyperactivity (in the pediatric population)</i>
Very Rare	<i>Somnolence</i>
Very Rare	<i>Tremor</i>
Very Rare	<i>Posterior Reversible Encephalopathy Syndrome</i>
Very Rare	<i>Reversible Cerebral Vasoconstriction Syndrome</i>
Common	<i>Impaired performance (impaired driving performance, poor work performance, incoordination, reduced motor skills, and impaired information processing)</i>
Common	<i>Sedation</i>
Not Known	<i>Activation of epileptogenic foci</i>
<b>Cardiac Disorders</b>	
Very Rare	<i>Arrhythmia</i>
Very Rare	<i>Myocardial infarction*</i>
Very Rare	<i>Palpitations</i>
Very Rare	<i>Tachycardia</i>
<b>Respiratory, Thoracic, and Mediastinal Disorders</b>	
Very Rare	<i>Epistaxis</i>
Common	<i>Dry nose</i>
<b>Gastrointestinal Disorders</b>	
Very Rare	<i>Abdominal Discomfort</i>
Very Rare	<i>Colitis ischaemic</i>
Very Rare	<i>Dry mouth</i>
Very Rare	<i>Nausea</i>
Very Rare	<i>Diarrhoea</i>
Very Rare	<i>Vomiting</i>
Common	<i>Constipation</i>

<b>Skin and Subcutaneous Tissue Disorders</b>	
Very Rare	<i>Pruritus</i>
Very Rare	<i>Angioedema</i>
Very Rare	<i>Pruritic rash</i>
Very Rare	<i>Rash</i>
Very Rare	<i>Urticaria</i>
Very Rare	<i>Acute generalised exanthematous pustulosis</i>
Very Rare	<i>Fixed eruption</i>
<b>Renal and Urinary Disorders</b>	
Very Rare	<i>Dysuria</i>
Very Rare	<i>Urinary retention</i>
Common	<i>Urinary hesitancy</i>
<b>General Disorders and Administration Site Conditions</b>	
Very Rare	<i>Fatigue</i>
Very Rare	<i>Feeling jittery</i>
<b>Investigations</b>	
Very Rare	<i>Blood pressure increased</i>
Very Rare	<i>Transaminases increased</i>
<b>Blood and lymphatic disorders</b>	
Rare	<i>Haematological reactions</i>
<b>Musculoskeletal and connective tissue disorders</b>	
Not known	<i>Muscle dyskinesias</i>
<b>Metabolism and nutrition disorders</b>	
Not known	<i>Appetite stimulation</i>
<b>Eye disorders</b>	
Not known	<i>Dry Eyes</i>
Not known	<i>Blurred vision</i>

\* These events have been reported very rarely in post-marketing safety. A recent postauthorisation safety study (PASS) did not provide any evidence of increased risk of myocardial infarction or cerebrovascular accident associated with the use of vasoconstrictors for nasal decongestion, including pseudoephedrine.

### Reporting suspected adverse effects

Reporting suspected adverse reactions after registration of the medicinal product is important. It allows continued monitoring of the benefit-risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions at [www.tga.gov.au/reporting-problems](http://www.tga.gov.au/reporting-problems).

## 4.9 Overdosage

If an overdose is taken or suspected, immediately contact the Poisons Information Centre (in Australia, call 13 11 26; in New Zealand call 0800 764 766) for advice, or go to a hospital straight away even if you feel well because of the risk of delayed, serious liver damage.

Overdosage with paracetamol if left untreated can result in severe, sometimes fatal liver damage, and rarely, acute renal tubular necrosis.

## 5 Pharmacological Properties

### 5.1 Pharmacodynamics properties

#### Mechanism of action

Pseudoephedrine has direct and indirect sympathomimetic activity and is an effective decongestant in the upper respiratory tract. It is a stereoisomer of ephedrine and has a similar action, but has been found to have less pressor activity and fewer central nervous system (CNS) effects.

Sympathomimetic agents are used as nasal decongestants to provide symptomatic relief. They act by causing vasoconstriction resulting in redistribution of local blood flow to reduce oedema of the nasal mucosa, thus improving ventilation, drainage and nasal stuffiness.

Paracetamol is a p-aminophenol derivative that exhibits analgesic and antipyretic activity. It does not possess anti-inflammatory activity. Paracetamol is thought to produce analgesia through a central inhibition of prostaglandin synthesis.

Triprolidine competes with histamine at central and peripheral histamine<sub>1</sub>-receptor sites, preventing the histamine-receptor interaction and subsequent mediator release.

Triprolidine is a highly lipophilic molecule that readily crosses the blood-brain barrier.

Triprolidine is highly selective for histamine<sub>1</sub>-receptors but has little effect on histamine<sub>2</sub> or histamine<sub>3</sub> receptors. Triprolidine also activates 5-hydroxytryptamine (serotonin) and  $\alpha$ -adrenergic receptors and blocks cholinergic receptors.

#### Clinical trials

No data available.

### 5.2 Pharmacokinetic Properties

Pseudoephedrine is readily absorbed from the gastrointestinal tract. It is largely excreted unchanged in the urine together with small amounts of its hepatic metabolite. It has a half-life of about 5-8 hours; elimination is enhanced and half-life reduced accordingly in acid urine. Small amounts are distributed into breast milk.



Paracetamol is readily absorbed from the gastrointestinal tract with peak plasma concentrations occurring about 10 to 60 minutes after oral administration. Paracetamol is distributed into most body tissues. Plasma protein binding is negligible at usual therapeutic doses but increases with increasing doses. The elimination half-life varies from about 1 to 3 hours.

Paracetamol is metabolised extensively in the liver and excreted in the urine mainly as inactive glucuronide and sulfate conjugates. Less than 5% is excreted unchanged. The metabolites of paracetamol include a minor hydroxylated intermediate which has hepatotoxic activity. This intermediate metabolite is detoxified by conjugation with glutathione; however, it can accumulate following paracetamol overdose (more than 150 mg/kg or 10 g total paracetamol ingested) and if left untreated can cause irreversible liver damage.

Paracetamol is metabolised differently by premature infants, newborns, infants and young children compared to adults, the sulfate conjugate being predominant.

After absorption from the gastro-intestinal tract, triprolidine hydrochloride is metabolised; a carboxylated derivative accounts for about half the dose excreted in the urine. Reported half-lives vary from 3 to 5 hours or more. Triprolidine is distributed into breast milk.

## **5.3 Preclinical safety data**

### **Genotoxicity**

No data available.

### **Carcinogenicity**

No data available.

## **6 Pharmaceutical Particulars**

### **6.1 List of excipients**

SUDAFED® Sinus + Allergy & Pain Relief tablets contain: brilliant blue FCF, microcrystalline cellulose, hydroxypropylcellulose, magnesium stearate, povidone, quinoline yellow.

### **6.2 Incompatibilities**

Incompatibilities were either not assessed or not identified as part of the registration of this medicine. Refer to Section 4.5 – Interactions with other medicines and other forms of interactions.

### **6.3 Shelf Life**

3 Years.

### **6.4 Special Precautions for storage**

Store below 25°C. Keep dry. Protect from light.

## 6.5 Nature and Contents of container

SUDAFED® Sinus + Allergy & Pain Relief tablets are available in blister packs (PVC/PVDC) of the following sizes:

- 4 tablets (S3) Pharmacist Only Medicine
- 20 tablets# (S3) Pharmacist Only Medicine

# marketed


## 6.6 Special Precautions for disposal

In Australia, any unused medicine or waste material should be disposed of in accordance with local requirements.


## 6.7 Physicochemical Properties

### Chemical Structure


Paracetamol



Pseudoephedrine Hydrochloride



Tripolidine Hydrochloride



## CAS number

Paracetamol

CAS Registry Number: 103-90-2

Pseudoephedrine Hydrochloride

CAS Registry Number: 345-78-8

Triprolidine Hydrochloride

CAS Registry Number: 6138-79-0

## 7 Medicine Schedule (Poisons Standard)

Schedule 3

## 8 Sponsor

Johnson & Johnson Pacific  
45 Jones Street  
Ultimo NSW 2007  
Australia

\*Registered trademark

## 9 Date of First Approval

28 September 2006

## 10 Date of Revision

16 Jan 2024

### Summary table of changes

Section Changed	Summary of new information
4.4 and 4.8	Added safety statements and adverse events.
Heading, 4.4 and 4.8	Additional safety statements and adverse events data. Inclusion of active ingredients in Product Information heading.
4.5	Updated to include interaction with Flucloxacillin.
4.8	Additional adverse drug reactions (ADRs) identified during post-marketing experience with pseudoephedrine
4.3 and 4.4	Revised special warning and precautions for use